A recent phase I trial has shown promising results for an annual injection of lenacapavir, a drug that could potentially protect against HIV infections for a full year. This development was announced at the Conference on Retroviruses and Opportunistic Infections in San Francisco, indicating that the drug remains present in the bloodstream at protective levels one year after administration.
Lenacapavir, already approved for treating HIV, emerged as an HIV prevention method after trials demonstrated its effectiveness. The drug prevented 100% of infections among women and adolescent girls in a previous study. It has shown efficacy in reducing HIV incidence by 96% in another study involving men and gender-diverse individuals.
The Potential of Lenacapavir
Although current preventative measures, such as daily pills and bi-monthly injections, are effective, lenacapavir promises a more convenient option, requiring only a yearly dose. This may reduce stigma and improve adherence, as it bypasses the need for frequent dosing.
Key Trial Developments
The annual injection trial featured 40 healthy volunteers and tested a new formulation of the drug at higher doses. Encouraging results suggest the potential for lenacapavir to become a key player in HIV prevention efforts. While regulatory approval is still pending, the company behind the drug is planning a large-scale phase III trial to further establish its efficacy.
Cost and Accessibility
Cost remains a consideration, especially for distribution in low- and middle-income countries, but licensing agreements aim to make affordable generic versions available in 120 regions. As the global HIV epidemic persists with high infection and mortality rates, lenacapavir could be a significant breakthrough, offering hope for reducing these numbers and eventually controlling the epidemic.
Source: Read more